Zura Bio price target lowered to $15 from $16 at Oppenheimer

Oppenheimer lowered the firm’s price target on Zura Bio (ZURA) to $15 from $16 and keeps an Outperform rating on the shares after the company reported year-end financial results and highlighted progress for ongoing trials of Tibulizumab in both Hidradenitis Suppurativa and Systemic Sclerosis. The company experienced a management transition in January with co-founder Sandeep Kulkarni adding to his board role with CEO position. The firm anticipates he will be important in positioning the company for clinical execution in 2026, with the first readout late this year in HS.